

## UNICHEM LABORATORIES LIMITED

Unichem Bhavan Prabhat Estate, Off S.V.Road, Jogeshwari (West), Mumbai - 400 102. Tel. No: +91 (22) 66 888 333

Fax. No: +91 (22) 267 843 91/ 5198 CIN: L99999MH1962PLC012451

## **Press Release**

Mumbai, Friday October 16, 2015

Unichem Laboratories receives ANDA approval from USFDA for Losartan Potassium Tablets USP

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for *Losartan Potassium Tablets USP*.

Losartan Potassium Tablets USP 25mg, 50mg and 100mg are therapeutically equivalent to Cozaar Tablets 25mg, 50mg and 100mg of Merck Sharp & Dohme Corp.

Losartan potassium is an angiotensin II receptor antagonist, indicated for Hypertension (as alone or in combination with other antihypertensive drugs), Hypertensive Patients with Left Ventricular Hypertrophy (to reduce the risk of stroke) and Nephropathy in Type 2 Diabetic Patients with Hypertension.

The product will be commercialized from Unichem's Ghaziabad plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur API Plant.





## **About Unichem Laboratories Limited**

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com

## For more information please contact:

Ms. Neema Thakore

Ph: +91-22-66888 404

E-mail: neema.thakore@unichemlabs.com

Mr. Rakesh Parikh/ Mr. Monish Shah

Ph: +91-22-66888 414

Ph: +91-22-66888 509

E-mail: rparikh@unichemlabs.com

monish.shah@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

